n/a 0.0 0.0%
Last Trade -
| Market Cap | £n/a |
| Enterprise Value | £n/a |
| Revenue | £27.0m |
| Position in Universe | th / 6633 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012E | 2013E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 3.22 | 4.91 | 24.8 | +177.5% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Singulex, Inc. is a commercial stage, next Generation Immunodiagnostics (NGI) company. The Company's single Molecule Counting (SMC) technology is a part of NGI, and provides ultra-sensitivity in the precision measurement of biomarkers. Powered by SMC technology, Singulex NGI commercial offerings are transforming patient care from reactive disease treatment to proactive health management. Singulex delivers SMC technology through its clinical lab. SMC technology can be applied to existing and newly identified biomarkers to aid physician decision making in cardiovascular, oncology, infectious disease, inflammation/immunology, and CNS applications. Its technology couples digital SMC technology with microparticle-based immunoassays to provide sensitivity and dynamic range. A biological sample (such as blood plasma) containing the analyte of interest is combined with paramagnetic micro-particles coated with capture antibodies and detection antibodies labeled with fluorescent dye.
| Last Annual | December 31st, 2011 |
| Last Interim | June 30th, 2012 |
| Incorporated | November 21, 1997 |
| No. of Shareholders: | n/a |
| No. of Employees: | 177 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | NYSE MKT (Dual Listing) |
| Shares in Issue | 590,107 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1701 Harbor Bay Pkwy Ste 200, ALAMEDA, 94502-3014, United States |
| Web | |
| Phone | +1 510 9959000 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of , shares in Singulex Inc are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in Singulex Inc are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Singulex Inc price has moved by % over the past year.
There are no analysts currently covering Singulex Inc.
Singulex Inc is scheduled to issue upcoming financial results on the following dates:
Singulex Inc does not currently pay a dividend.
Singulex Inc does not currently pay a dividend.
Singulex Inc does not currently pay a dividend.
To buy shares in Singulex Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Singulex Inc are currently trading at n/a, giving the company a market capitalisation of £n/a.
Here are the trading details for Singulex Inc:
We were not able to load our ranking data for Singulex Inc
We were not able to load any forecast data for Singulex Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Singulex Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Singulex Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Singulex Inc.
We were unable to find the directors for Singulex Inc.
Here are the top five shareholders of Singulex Inc based on the size of their shareholding:
